TABLE 4.

PTA of single-dose cefoxitin regimens in obese patients with BMIs of >30 kg/m² against Escherichia coli, Bacteroides fragilis, and Staphylococcus aureus

Compartment and pharmacodynamic target	Cefoxitin dose	PTA by pathogen (%)a
		E. coli at indicated time after dose (h)				B. fragilis at indicated time after dose (h)				S. aureus at indicated time after dose (h)
		1	2	3	4	1	2	3	4	1	2	3	4
Serum
fT>MIC of 100%	40 mg/kg	97	95	76	46	92	79	47	18	100	100	78	36
	2 g	89	68	37	14	74	36	10	2	100	68	19	3
	2 g in nonobese patients (from reference 34)	98	35	12	4	69	13	3	0	98	35	12	4
fT>MIC of 70%	40 mg/kg	98	95	91	80	94	90	77	54	100	100	99	84
	2 g	92	84	66	42	82	60	32	13	100	95	62	26
Tissue
fT>MIC of 100%	40 mg/kg	27	7	2	1	0	0	0	0	55	26	8	2
	2 g	4	1	0	0	0	0	0	0	17	3	1	0
fT>MIC of 70%	40 mg/kg	38	16	6	3	0	0	0	0	63	44	26	10
	2 g	6	2	0	0	0	0	0	0	25	10	3	0

^aValues meeting the desired goal of PTA of ≥90% at each time point are in bold.